In December 2016, pembrolizumab monotherapy was approved, and in February 2017 reimbursed, as the first immune checkpoint inhibitor (ICI) of programmed death 1 (PD-1)/PD-L1 available in Japan for advanced NSCLC in the first-line setting. This evidence concerns the gene CD274 and non-small cell lung carcinoma.